Artemilife

What Artemilife does

ArtemiLife Incorporated is a Delaware-incorporated health and wellness company that develops and sells clinically tested coffee and tea products infused with artemisinin derived from Artemisia annua (sweet wormwood). Founded in 2017, the company cultivates Artemisia annua in former tobacco fields outside Lexington, Kentucky, working with the Tobacco Research Development Center, the University of Kentucky Markey Cancer Center (an NCI-designated cancer center), and the University of Kentucky. The U.S. operating entity (ArtemiLife Incorporated, Dover, DE) sells products under the ArtemiLife, ArtemiCafe, and ArtemiTea trademarks, which are owned by and licensed from ArtemiFlow GmbH in Germany.

The company's core technology is a patent-pending formulation that uses coffee as a vehicle to stabilize artemisinin, addressing a known shelf-life and dosing challenge with the compound and enabling precise, reproducible single-serve doses through K-Cup-style pod delivery. Its product portfolio comprises ArtemiCafe Decaf, ArtemiCafe Dark Roast, and ArtemiCafe Light Roast coffees, plus ArtemiTea Chai Tea, all packaged in 30-count boxes or pouches. ArtemiLife is running a Phase 2 clinical trial at the University of Kentucky Markey Cancer Center evaluating ArtemiCafe Decaf as maintenance therapy for men with biochemical recurrence of prostate cancer; a Phase 1 dose-escalation trial in advanced ovarian cancer previously demonstrated safety and tolerability at up to four cups daily. These clinical programs anchor the company's 'Clinically Tested Coffee. Backed by Science.' positioning.

ArtemiLife operates a direct-to-consumer e-commerce model exclusively through its online storefront at store.artemilife.com, shipping to all 50 U.S. states via USPS Standard First Class. It offers one-time purchases (10% off first order) and monthly auto-ship subscriptions (25% off first subscription, billed and shipped every 30 days) that customers can pause, resume, or cancel via an account portal. The company targets two overlapping segments: health-conscious consumers seeking science-backed daily wellness products, and cancer patients/survivors (prostate and ovarian) interested in maintenance therapy. Products are manufactured domestically, and the company has stated intent to pursue international expansion, although current operations are U.S.-only. The company has 11-50 employees and a single disclosed funding round of $299,999 in January 2020.

Name

Artemilife

Legal name

ArtemiLife Incorporated

Website

https://artemilife.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

ArtemiLife Incorporated sells direct-to-consumer coffee and tea products infused with stabilized artemisinin from Artemisia annua, targeting health-conscious consumers and cancer maintenance therapy patients through subscription and one-time e-commerce sales across all 50 U.S. states.

Ownership category

akta.pro rank

Product category

Functional Beverages

NAICS

Coffee and Tea Manufacturing (311920), Coffee and Tea Manufacturing (31192), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Botanical/Herbal & Adaptogen Functional Beverage Production (AFAFAFAF)

akta.pro secondary industries

Natural Extracts & Botanical Concentrates for Beverages (herbal, spice, aromatic extracts) (AFAFAGAJ), Instant Tea, Tea Extracts & Concentrates Manufacturing (AFAFADAH), Herbal & Botanical Supplements (CRADAGAD)

Keywords

• Functional beverages
• Artemisinin supplements
• Specialty coffee pods
• Herbal wellness tea
• Clinical nutrition products

Headquarters

HQ city

Claymont

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel

Revenue model

1. ArtemiCafe Product Sales: ArtemiLife generates revenue through direct-to-consumer sales of ArtemiCafe coffee products (Decaf, Dark Roast, Light Roast) and ArtemiTea chai tea. Products are sold in boxes of 30 pods or tea bags through the company's e-commerce platform, with both one-time purchases and subscription options available.
2. Subscription (Auto-ship): Monthly subscription model processed every 30 days with 25% discount off first subscription. Subscribers can manage frequency, quantity, shipping address, and can pause or cancel subscriptions through their account portal.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

ArtemiLife produces and sells coffee and tea products infused with artemisinin derived from Artemisia annua (sweet wormwood). Its core lineup—ArtemiCafe (Decaf, Dark Roast, Light Roast) and ArtemiTea Chai Tea—is sold in single-serve pods or tea bags via a direct-to-consumer e-commerce storefront with subscription options, and is being clinically investigated for use as maintenance therapy in prostate and ovarian cancer patients.

Product overview

ArtemiLife is a health and wellness company offering a portfolio of Artemisia annua-infused coffee and tea products. The core product line includes ArtemiCafe (available in Decaf, Dark Roast, and Light Roast varieties) and ArtemiTea Chai Tea. All products utilize Artemisia annua (sweet wormwood), a plant used for over 2000 years, grown in Kentucky using patent-pending technology. The products deliver a precise and reproducible dose of artemisinin, with Phase 1 clinical trials demonstrating safety and non-toxicity. ArtemiCafe Decaf is currently undergoing Phase 2 clinical trials for prostate cancer maintenance therapy at University of Kentucky Markey Cancer Center.

Differentiator

Problem solved

Functional benefit

Brands

• ArtemiCafe: Clinically tested coffee infused with Artemisia annua, available in Decaf, Dark Roast, and Light Roast varieties.
• ArtemiTea

Products and services

• ArtemiCafe Decaf Decaffeinated coffee infused with Artemisia annua (sweet wormwood), designed for daily consumption with potential anti-cancer properties and currently undergoing Phase 2 clinical trial for prostate cancer maintenance therapy at University of Kentucky Markey Cancer Center. Sold in boxes of 30 single-serve pods via the ArtemiLife e-commerce store, available as one-time purchase or monthly subscription.
• ArtemiCafe Dark Roast

Quantifiable outcome

• Phase 1 trial: Safe to drink up to 4 times daily with no dose-limiting toxicity observed
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• University of Kentucky Markey Cancer CentercoreStrategic or Co-development Partner · 1 August 2023University of Kentucky Markey Cancer Center researchers are conducting independent Phase 1 and Phase 2 clinical trials of ArtemiCafe products. Phase 1 dose escalation trial investigated ArtemiCafe in women with advanced ovarian cancer (Stage II-IV). Phase 2 trial is investigating ArtemiCafe Decaf in men with biochemical recurrence of prostate cancer. Both trials examine the product as maintenance therapy. The Markey Cancer Center is an NCI-designated cancer center, providing clinical trial credibility and regulatory-grade research validation.
• Tobacco Research Development CentercoreStrategic or Co-development Partner · 1 January 2017Collaboration with Tobacco Research Development Center has resulted in a highly scalable manufacturing process for ArtemiCafe products, producing a pesticide-free product with reproducibly high levels of artemisinin from Kentucky-grown Artemisia annua.
• University of KentuckycoreStrategic or Co-development Partner · 1 January 2017Ongoing collaborations with University of Kentucky researchers combined with Tobacco Research Development Center and Markey Cancer Center expertise. The partnership has enabled development of proprietary cultivation techniques and manufacturing processes for consistent, high-quality artemisinin delivery through coffee products.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• MUD\WTR: MUD\WTR markets an adaptogen-coffee alternative as a daily functional beverage subscription via D2C. Like ArtemiLife, it targets health-conscious consumers seeking evidence-positioned coffee replacements, though it lacks an oncology clinical program.
• Rasa: Rasa sells adaptogenic herbal coffee alternatives D2C with a subscription model. Comparable to ArtemiLife in go-to-market (D2C, subscription, adaptogen-positioned coffee) and target persona (wellness-focused consumers), though without clinical-trial validation.
• Four Sigmatic: Four Sigmatic sells mushroom- and adaptogen-infused coffee and functional beverages direct-to-consumer via subscription. It is the closest analog to ArtemiLife's botanical-functional-coffee positioning, differing only in the active ingredient (functional mushrooms vs. artemisinin from Artemisia annua).
• Ryze Superfoods: Ryze markets a mushroom-coffee blend directly to consumers. Similar functional-beverage D2C subscription positioning to ArtemiLife, targeting the same daily-wellness routine with botanical actives rather than artemisinin.
• Cuzen Matcha: Cuzen sells fresh-ground matcha with a focus on ceremonial-grade, functional positioning and D2C subscriptions. Comparable to ArtemiLife in single-serve premium functional-beverage D2C and consumer wellness positioning.

Broad incumbents

• Keurig Dr Pepper: Keurig Dr Pepper owns the dominant single-serve pod platform. While it does not compete in botanical-functional coffee, its pod ecosystem defines the distribution and format standard that ArtemiLife's single-serve pods compete within.
• Himalaya Wellness: Himalaya Wellness is a large herbal/botanical supplements brand with global distribution. Comparable to ArtemiLife in botanical-ingredient sourcing and herbal-positioning, though at much larger scale and without coffee-based delivery.
• La Colombe Coffee Roasters: La Colombe is an established specialty coffee roaster with broad D2C and foodservice distribution. It is a broader-incumbent benchmark on single-serve premium coffee, though it does not pursue botanical-functional or clinical positioning.
• Yogi Tea (East West Tea Company): Yogi Tea is a major functional-herbal tea brand with broad retail and D2C distribution. It overlaps with ArtemiLife's ArtemiTea chai product in herbal-tea delivery format and wellness positioning, though at significantly larger scale.

Emerging players

• Standard Process: Standard Process is a whole-food and botanical supplement manufacturer with practitioner and D2C channels. Comparable to ArtemiLife in botanical-supply chain and health-positioning, though it focuses on encapsulated supplements rather than coffee delivery.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ArtemiLife
• Facebookfacebook.com/ArtemiLife

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artemilife